Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study to Determine the Safety and Efficacy of Incorporating Hyperbaric Oxygen Therapy Into RIC Fludarabine and Melphalan and Allogeneic Hematopoietic Stem/Progenitor Transplantation

NCT03964506 is registered in ClinicalTrials.gov with Omar Aljitawi as lead sponsor.

NCT NCT03964506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03964506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study to Determine the Safety and Efficacy of Incorporating Hyperbaric Oxygen Therapy Into RIC Fludarabine and Melphalan and Allogeneic Hematopoietic Stem/Progenitor Transplantation
Lead sponsor
Omar Aljitawi
Phase
Phase 1
Overall status
Recruiting
Start date
July 1, 2020
Completion date
March 1, 2028
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, atypical chronic myeloid leukemia, chronic monocytic leukemia, chronic myelomonocytic leukemia, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasm, myelofibrosis